Skip to Content

The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.

Elvitegravir Dosage

Applies to the following strength(s): 85 mg ; 150 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for HIV Infection

With once-daily atazanavir/ritonavir or twice-daily lopinavir-ritonavir: 85 mg orally once a day with food
With twice-daily darunavir/ritonavir, fosamprenavir/ritonavir, or tipranavir/ritonavir: 150 mg orally once a day with food

Comments:
-The manufacturer product information should be consulted for the recommended dosing regimen for atazanavir/ritonavir, lopinavir-ritonavir, darunavir/ritonavir, fosamprenavir/ritonavir, or tipranavir/ritonavir; this drug should not be used with other dose regimens or HIV-1 protease inhibitors.
-This drug should not be used with cobicistat and protease inhibitors.

Use: In combination with a ritonavir-boosted HIV protease inhibitor and at least 1 other antiretroviral drug, for the treatment of HIV-1 infection in antiretroviral therapy-experienced patients

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Mild or moderate liver dysfunction (Child-Pugh A or B): No adjustment recommended.
Severe liver dysfunction (Child-Pugh C): Not recommended.

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Comments: This drug is highly protein-bound; significant removal via hemodialysis or peritoneal dialysis is not likely.

Other Comments

Administration advice:
-Administer with food.
-Use in combination with a ritonavir-boosted protease inhibitor and at least 1 other antiretroviral drug.
-Administer antacids at least 2 hours before or after this drug.

Storage requirements:
-Store below 30C (86F) in original bottle

General:
-Treatment history and resistance testing (if available) should guide the use of elvitegravir-containing regimens.
-The manufacturer product information for the coadministered protease inhibitor, ritonavir, and other coadministered antiretroviral drugs should be consulted.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide